Literature DB >> 28992561

Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology.

R E Kibbelaar1, B E Oortgiesen2, A M van der Wal-Oost3, K Boslooper4, J W Coebergh5, N J G M Veeger6, P Joosten7, H Storm8, E N van Roon9, M Hoogendoorn7.   

Abstract

Randomised clinical trials (RCTs) are considered the basis of evidence-based medicine. It is recognised more and more that application of RCT results in daily practice of clinical decision-making is limited because the RCT world does not correspond with the clinical real world. Recent strategies aiming at substitution of RCT databases by improved population-based registries (PBRs) or by improved electronic health record (EHR) systems to provide significant data for clinical science are discussed. A novel approach exemplified by the HemoBase haemato-oncology project is presented. In this approach, a PBR is combined with an advanced EHR, providing high-quality data for observational studies and support of best practice development. This PBR + EHR approach opens a perspective on randomised registry trials.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Electronic health record; Evidence-based medicine; Haematology; Oncology; Population-based registry; Randomised clinical trial

Mesh:

Year:  2017        PMID: 28992561     DOI: 10.1016/j.ejca.2017.09.007

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

1.  Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.

Authors:  Emanuel Raschi; Alessandra Mazzarella; Ippazio Cosimo Antonazzo; Nicolò Bendinelli; Emanuele Forcesi; Marco Tuccori; Ugo Moretti; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

2.  Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.

Authors:  Johanne Rozema; Mels Hoogendoorn; Robby Kibbelaar; Eva van den Berg; Nic Veeger; Eric van Roon
Journal:  Blood Adv       Date:  2021-03-09

3.  Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.

Authors:  Johanne Rozema; Eric N van Roon; Robby E Kibbelaar; Nic J G M Veeger; Christiaan L Slim; Harry de Wit; Mels Hoogendoorn
Journal:  Transfusion       Date:  2021-09-03       Impact factor: 3.337

4.  Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.

Authors:  Alice Pisana; Björn Wettermark; Amanj Kurdi; Biljana Tubic; Caridad Pontes; Corinne Zara; Eric Van Ganse; Guenka Petrova; Ileana Mardare; Jurij Fürst; Marta Roig-Izquierdo; Oyvind Melien; Patricia Vella Bonanno; Rita Banzi; Vanda Marković-Peković; Zornitsa Mitkova; Brian Godman
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

5.  Harms in Systematic Reviews Paper 1: An introduction to research on harms.

Authors:  Riaz Qureshi; Evan Mayo-Wilson; Tianjing Li
Journal:  J Clin Epidemiol       Date:  2021-11-03       Impact factor: 7.407

6.  Self-matched learning to construct treatment decision rules from electronic health records.

Authors:  Tianchen Xu; Yuan Chen; Donglin Zeng; Yuanjia Wang
Journal:  Stat Med       Date:  2022-05-05       Impact factor: 2.497

7.  Using digital technologies in clinical trials: Current and future applications.

Authors:  Carmen Rosa; Lisa A Marsch; Erin L Winstanley; Meg Brunner; Aimee N C Campbell
Journal:  Contemp Clin Trials       Date:  2020-11-17       Impact factor: 2.226

8.  A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study.

Authors:  Johanne Rozema; Christiaan L Slim; Nic J G M Veeger; Robby E Kibbelaar; Harry de Wit; Eric N van Roon; Mels Hoogendoorn
Journal:  Blood Transfus       Date:  2020-12-16       Impact factor: 3.443

9.  Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study.

Authors:  Junjie Hang; Lixia Wu; Lina Zhu; Zhiqiang Sun; Ge Wang; Jingjing Pan; Suhua Zheng; Kequn Xu; Jiadi Du; Hua Jiang
Journal:  Cancer Med       Date:  2018-06-01       Impact factor: 4.452

10.  Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data.

Authors:  Ashley M Hopkins; Adel Shahnam; Sasha Zhang; Chris S Karapetis; Andrew Rowland; Michael J Sorich
Journal:  Cancer Biol Med       Date:  2019-05       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.